Skye Bioscience (SKYE) News Today → Elon Musk’s Next Move Will Disrupt AI Forever (From InvestorPlace) (Ad) Free SKYE Stock Alerts $12.15 +0.74 (+6.49%) (As of 09:01 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13 at 8:05 PM | marketbeat.comSkye Bioscience (NASDAQ:SKYE) Announces Quarterly Earnings ResultsSkye Bioscience (NASDAQ:SKYE - Get Free Report) announced its earnings results on Friday. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.02).May 12 at 7:40 PM | nasdaq.comSkye Bioscience, Inc. Common Stock (SKYE) Dividend HistoryMay 12 at 7:40 PM | finance.yahoo.comSkye Bioscience, Inc.'s (NASDAQ:SKYE) last week's 13% decline must have disappointed private equity firms who have a significant stakeMay 10, 2024 | globenewswire.comSkye Bioscience Highlights Novel Synthetic Cannabinoid-based Library Capable of Modulating the Endocannabinoid System to Treat Ocular Diseases at ARVO 2024 Annual MeetingMay 10, 2024 | americanbankingnews.comContrasting Skye Bioscience (SKYE) and Its RivalsMay 9, 2024 | americanbankingnews.comSkye Bioscience (NASDAQ:SKYE) Trading Down 1.8%May 9, 2024 | americanbankingnews.comSkye Bioscience (NASDAQ:SKYE) Shares Down 1.8% April 30, 2024 | globenewswire.comSkye Bioscience to Present Two Posters at Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual MeetingApril 23, 2024 | globenewswire.comSkye Bioscience to Present at Upcoming Investment ConferencesApril 19, 2024 | investorplace.comThese 3 Small-Cap Stocks Are Up 304% in 2024. Can They Run Higher?April 18, 2024 | morningstar.comSkye Bioscience Inc Ordinary SharesApril 16, 2024 | investorplace.comThese 3 Biotech Stocks Are Up 269% in 2024. Is There More to Come?April 12, 2024 | marketbeat.comSkye Bioscience (OTCMKTS:SKYE) Coverage Initiated by Analysts at OppenheimerOppenheimer started coverage on Skye Bioscience in a report on Friday. They issued an "outperform" rating and a $25.00 target price on the stock.April 10, 2024 | finanznachrichten.deSkye Bioscience, Inc.: Skye Bioscience Uplists to The Nasdaq Global MarketApril 10, 2024 | globenewswire.comSkye Bioscience Uplists to The Nasdaq Global MarketMarch 27, 2024 | marketbeat.comSkye Bioscience, Inc. (OTCMKTS:SKYE) Short Interest UpdateSkye Bioscience, Inc. (OTCMKTS:SKYE - Get Free Report) was the target of a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 34,400 shares, a growth of 631.9% from the February 29th total of 4,700 shares. Based on an average daily trading volume, of 129,100 shares, the short-interest ratio is presently 0.3 days.March 15, 2024 | msn.comMercedes Mone Drops Julia Hart, Willow Nightingale Gets Main Event Win On AEW DynamiteMarch 14, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Guardant Health (GH), Cue Health (HLTH) and Skye Bioscience (OtherSKYE)March 13, 2024 | marketbeat.comSkye Bioscience, Inc. (OTCMKTS:SKYE) Sees Significant Growth in Short InterestSkye Bioscience, Inc. (OTCMKTS:SKYE - Get Free Report) saw a large growth in short interest in February. As of February 29th, there was short interest totalling 4,700 shares, a growth of 46.9% from the February 14th total of 3,200 shares. Based on an average daily trading volume, of 103,800 shares, the days-to-cover ratio is currently 0.0 days.March 13, 2024 | finanznachrichten.deSkye Bioscience, Inc.: Skye Bioscience Announces $40 Million Private Placement Equity FinancingMarch 8, 2024 | investorplace.comAll Three of Our Analysts AgreeMarch 4, 2024 | globenewswire.comSkye Bioscience Appoints Dr. Annalisa Jenkins to Board of DirectorsFebruary 26, 2024 | globenewswire.comSkye Bioscience Completes Enrollment of Phase 2a Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular HypertensionFebruary 7, 2024 | finance.yahoo.comSkye Bioscience to Present at Oppenheimer Investor ConferenceFebruary 6, 2024 | markets.businessinsider.comBuy Rating Affirmed for Skye Bioscience on Strong Drug Pipeline and Financial HealthJanuary 30, 2024 | msn.comSkye Bioscience Announces Private Placement DetailsJanuary 30, 2024 | msn.comSkye Bioscience Strikes Deal for $50M Capital BoostJanuary 29, 2024 | msn.comSkye Bioscience announces $50M private placementJanuary 29, 2024 | finance.yahoo.comSkye Bioscience Announces $50.25 Million Private Placement Equity FinancingDecember 11, 2023 | msn.comGlobal Cannabis Odyssey: Ontario Expansion, Australian Exports And Innovations In AfricaDecember 11, 2023 | finance.yahoo.comSkye Announces Clinical Development Plan in Obesity for Differentiated Peripheral CB1 Inhibitor, NimacimabDecember 5, 2023 | finance.yahoo.comSkye Bioscience and Tautomer Bioscience Enter Exclusive License for SBI-100 for Development and Sale of Products for Chronic Pain and Other Indications in South Africa and Rest of AfricaNovember 21, 2023 | finance.yahoo.comSkye Bioscience to Present at BTIG Ophthalmology Day and OIS XIII Ophthalmology Innovation SummitNovember 20, 2023 | thetimes.co.ukSkye McAlpine’s easy one-tray dinner recipesNovember 10, 2023 | mirror.co.ukMatthew Perry's ex co-star Ione Skye shares heartbreaking last texts with Friends actorNovember 8, 2023 | morningstar.comSkye Bioscience Inc Ordinary Shares SKYEOctober 26, 2023 | msn.comSkye Bioscience posts early-stage data for glaucoma therapyOctober 25, 2023 | finance.yahoo.comSkye Bioscience Announces Positive Phase 1 Trial Results for SBI-100 Ophthalmic Emulsion, Its First-in-Class CB1 Agonist Being Developed for the Treatment of GlaucomaOctober 20, 2023 | finance.yahoo.comCORRECTION: Skye Bioscience to Host Virtual Investor Day on October 25, 2023: "CB1 Axis: Unlocking the Pharmaceutical Potential of the Endocannabinoid System"October 10, 2023 | thetimes.co.ukSkye McAlpine’s cakes with carrot, sweet potato and pumpkinOctober 1, 2023 | bbc.comHeritage award for 89-year-old Skye ferry crossingSeptember 27, 2023 | finance.yahoo.comSkye Bioscience Receives Clinical Site Approvals for Glaucoma Phase 2a TrialSeptember 5, 2023 | finance.yahoo.comSkye Bioscience to Present at H.C. Wainwright 25th Annual Global Investment ConferenceAugust 14, 2023 | finance.yahoo.comSkye Bioscience to Present at H.C. Wainwright 3rd Annual Ophthalmology Virtual ConferenceJuly 13, 2023 | finance.yahoo.comSkye Bioscience Receives Positive Safety Review for Final Cohort of Fully-Enrolled Phase 1 Study of SBI-100 Ophthalmic EmulsionJuly 6, 2023 | msn.comSkye Completes Production Of Cannabinoid Based Drug In Preparation For Glaucoma Clinical TrialJune 9, 2023 | travel.usnews.comIsle of SkyeJune 5, 2023 | finance.yahoo.comSkye Bioscience to Present at LD Micro Invitational XIIIMay 15, 2023 | finance.yahoo.comSkye Bioscience Receives Positive Safety Review in First Multiple-Administration Cohort of Phase 1 Study of SBI-100 Ophthalmic EmulsionApril 29, 2023 | finance.yahoo.comSkye Bioscience, Inc. (SKYE) Stock Historical Prices & Data - Yahoo Finance Get Skye Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for SKYE and its competitors with MarketBeat's FREE daily newsletter. Email Address Look Who Fired the World’s Richest Man (Ad)This company is tiny… but already has contracts with 30 federal agencies and services some of the biggest companies in the U.S. And demand for the technology is unprecedented … “unlike anything we have seen in the past,” says a spokesman. Get the full story here. SKYE Media Mentions By Week SKYE Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SKYE News Sentiment▼-0.240.56▲Average Medical News Sentiment SKYE News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SKYE Articles This Week▼101▲SKYE Articles Average Week Get Skye Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for SKYE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: INCR News CRVO News RGLS News IMAB News SGMT News RPTX News MCRB News PDSB News CTMX News IXHL News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SKYE) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersDid Intel Just Dethrone Nvidia?Chaikin AnalyticsCharles Payne Demystifies OptionsUnstoppable ProsperityRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressElon to Transform U.S. Economy? Porter & CompanyThe only AI company you should be looking atBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Skye Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
